NIH Begins Trial On mRNA-Based Universal Flu Vaccine

May 15, 2023 Medicine, Science

Patients are now enrolling in an early stage clinical trial to test a universal flu vaccine based on messenger RNA technology, the National Institutes of Health announced Monday.

Scientists hope the vaccine will protect against a wide variety of flu strains and provide long-term immunity so people do not have to receive a shot every year. Messenger RNA, or mRNA, is the technology behind Moderna’s and Pfizer’s widely used Covid vaccines. NIH played a crucial role in developing the mRNA platform used by Moderna.

The universal shot was developed by researchers at the National Institute of Allergy and Infectious Diseases. The clinical trial is enrolling volunteers at Duke University in Durham, North Carolina.

Read the full article.

News: Clinical trial of mRNA universal influenza vaccine candidate begins https://t.co/O8vGRNABPH

— NIH (@NIH) May 15, 2023